Recently a shift of paradigm has occurred toward radiolabeled GRPR-antagonists that, besides their higher inherent biosafety, have unexpectedly shown superior tumor targeting and faster background clearance from the body compared to agonists [11,12]. The gene discussed is GRPR; the disease is neoplasm.